WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression ... given to 140,000 patients worldwide. Side effects include sleepiness, fainting ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato ... Because reported side-effects include temporary nausea, vomiting, and ...

Since there are some side effects, including sedation, respiratory depression and misuse, Spravato is only available through a restricted program. The nasal spray has undergone more than a decade ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food ... It’s already been given to 140,000 patients worldwide. Side effects include sleepiness, fainting, dizziness, anxiety ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

Overusing nasal sprays can also lead to rebound congestion. If you have been using a nasal spray for three days and your symptoms aren’t any better, they’re getting worse, or you have serious side ...

PAUL HUNTER was an iconic snooker player when he was alive and his legacy has continued long after his death aged just 27. Every year at the Masters tournament the sportsman is remembered ...